Sign in
RAPP Stock Price, Chart, Stats & News
Rapport Therapeutics, Inc. Common Stock
Save
Rapport Therapeutics, Inc. Common Stock (RAPP) does not currently pay a dividend.
1.62B
Market cap
–
Current P/E
–
Forward P/E
RAPP chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -21.76% |
ROE | -28.85% |
D/E | 0.02x |
Interest coverage ratio | – |
RAPP valuation
P/E | – |
P/S | – |
P/B | 2.70x |
P/CF | -14.95x |
P/FCF | -11.56x |
P/OCF | -14.95x |
PEG | 0.32x |
EV multiple | -8.52x |
About
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder.
Similar securities
Based on sector and market capitalization
Report issue